NCT03202095

Creatine for Treatment of Depression Associated With Type 2 Diabetes

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Utah · Academic / Other
• Sex: Female
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesize that the administration of a widely available, naturally occurring dietary supplement, creatine monohydrate, will reduce the severity of depression in individuals with type 2 diabetes. The purpose of this study is to determine whether 12 weeks of creatine supplementation is an effective treatment for depression in individuals with type 2 diabetes.

Detailed description

Depression is a debilitating illness associated with diminished quality of life and significant personal and societal costs. Depression is twice as common in those with type 2 diabetes compared to the general population. Antidepressants are commonly prescribed as treatment for depression; however, they may not be the optimal treatment for people with type 2 diabetes. Creatine has been shown to decrease symptoms of depression in many types of individuals when used over the course of 8 weeks or more. The purpose of this study is to investigate whether creatine can decrease symptoms of depression in individuals with type 2 diabetes when taken daily for 12 weeks. This study also investigates how creatine impacts brain chemistry as creatine decreases depressive symptoms.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Creatine Monohydrate	5 grams daily of oral creatine monohydrate powder.

Timeline

• Start date: 2017-08-01
• Primary completion: 2024-06-10
• Completion: 2024-06-10
• First posted: 2017-06-28
• Last updated: 2024-06-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study